| Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912) |
|---|
| 12/06/2001 | WO2001053351A3 Apoptin bindendes protein |
| 12/06/2001 | WO2001051474A3 Polypharmacophoric agents |
| 12/06/2001 | WO2001049673A3 Compounds and methods for modulation of estrogen receptors |
| 12/06/2001 | WO2001046392A3 Homologues of human heparanase and splice variants thereof |
| 12/06/2001 | WO2001046178A3 Substituierte bisindolymaleimide |
| 12/06/2001 | WO2001045741A3 Methods for preparing pharmaceutical formulations |
| 12/06/2001 | WO2001045732A3 Method and composition for treatment and/or prevention of antibiotic-resistant microorganism infections |
| 12/06/2001 | WO2001044167A8 Quaternary ammonium compounds and their use as anti-tussive agents |
| 12/06/2001 | WO2001041734A3 Stable galenic preparations comprising a benzimidazol and method for the production thereof |
| 12/06/2001 | WO2001041704A3 Method for the prevention and/or treatment of atherosclerosis |
| 12/06/2001 | WO2001041702A3 Zinc thiosalicylate, dermatological compositions containing same, in particular in the form of a self-adhesive device and method for preparing same |
| 12/06/2001 | WO2001040348A3 Amorphous polymeric polyaxial initiators and compliant crystalline copolymers therefrom |
| 12/06/2001 | WO2001040315A9 The alginate having low molecular weight, methods of manufacturing it and its use |
| 12/06/2001 | WO2001040229A3 Method for producing epinastine hydrochloride in the high-melting crystal modification |
| 12/06/2001 | WO2001034201A3 Methods for inhibiting neurofibromatosis type 1 (nf1) |
| 12/06/2001 | WO2001034138B1 Compositions and methods for treatment of neurological disorders and neurodegenerative diseases |
| 12/06/2001 | WO2001034130A9 Therapy for human cancers using cisplatin and other drugs or genes encapsulated into liposomes |
| 12/06/2001 | WO2001032127A3 Method and compositions for treating pulmonary diseases |
| 12/06/2001 | WO2001032031A3 Cholesterol reducing sterol compositions, preparation and method of use |
| 12/06/2001 | WO2001030381A3 Use of csf-1 inhibitors |
| 12/06/2001 | WO2001024788A3 Treating endometriosis or infertility, or improving fertility |
| 12/06/2001 | WO2001023362A3 Rate-controlled particles |
| 12/06/2001 | WO2001022977A3 Echinacea supplement and method of manufacture |
| 12/06/2001 | WO2001021605A8 Method for extracting compounds of furan lipids and polyhydroxylated fatty alcohols of avocado, composition based on said compounds and use of said compounds in therapy, cosmetics and food |
| 12/06/2001 | WO2001019800A3 Mediators of hedgehog signaling pathways, compositions and uses related thereto |
| 12/06/2001 | WO2001017999A3 Amino-triazolopyridine derivatives |
| 12/06/2001 | WO2001016345A3 Sequence-specific dna recombination in eukaryotic cells |
| 12/06/2001 | WO2001012775A8 25 human secreted proteins |
| 12/06/2001 | WO2001010848A3 Diazocin-dione derivatives and their use s tryptase inhibitors |
| 12/06/2001 | WO2001010847A8 Novel integrin receptor antagonists |
| 12/06/2001 | WO2001007021A3 Process for the improvement of spermatozoa fertilization activity |
| 12/06/2001 | WO2001007015A3 Quick-release extrudates, method for preparing the same and compositions obtained from said extrudates |
| 12/06/2001 | WO2001001972A3 SELECTIVE iGluR5 RECEPTOR ANTAGONISTS FOR THE TREATMENT OF MIGRAINE |
| 12/06/2001 | WO2001000193A3 Zinc ionophores as anti-apoptotic agents |
| 12/06/2001 | WO2000077233A3 Complement-resistant non-mammalian dna viruses and uses thereof |
| 12/06/2001 | WO2000077018A3 Purine derivatives |
| 12/06/2001 | WO2000071101A3 Methods and compounds for inhibiting amyloid deposits |
| 12/06/2001 | WO2000064427A3 Lamivudine containing pharmaceutical formulation |
| 12/06/2001 | WO2000062808A8 Cobalamin conjugates useful as antitumor agents |
| 12/06/2001 | WO2000047193A3 Inhibition of angiogenesis with epigallocatechin-3-gallate |
| 12/06/2001 | US20010049446 C-C9-Heteroaryl, linked via C or N, substituted or unsubstitued by 1,3-substituents, substituted benzoylguanidine derivatives useful for treating ischemia, cardiac infarct, angina pectoris, and storke etc. |
| 12/06/2001 | US20010049445 Process for the preparation of thiazolidinedione derivatives |
| 12/06/2001 | US20010049444 Pyridine-substituted benzanilides as potassium ion channel openers |
| 12/06/2001 | US20010049442 Paroxetine compositions |
| 12/06/2001 | US20010049441 An azaindole derivative useful for antagonizing 5-HT6 receptor |
| 12/06/2001 | US20010049439 Therapeutic polymorphs of a GABA-A alpha-5 inverse agonist and pamoate formulations of the same |
| 12/06/2001 | US20010049396 Symptomatic relief |
| 12/06/2001 | US20010049395 Method of induction of cell differentiation of malignant cells such leukemia |
| 12/06/2001 | US20010049394 For example depression and anxiety, comprising orally administering deramciclane in a daily dosage of about 20 to about 60 mg. |
| 12/06/2001 | US20010049392 Inhibition of IgA production |
| 12/06/2001 | US20010049391 Tramadol or a pharmaceutically acceptable derivative or salt thereof and a carrier |
| 12/06/2001 | US20010049388 Administering a prophylactically effective amount of an HMG-CoA reductase inhibitor alone or in combination with another lipid altering agent |
| 12/06/2001 | US20010049387 Use in the treatment of cancer, as tubulin polymerizers and as microtubule stabilization agents. |
| 12/06/2001 | US20010049386 Method of treating onychomycosis |
| 12/06/2001 | US20010049384 Method of treatment and pharmaceutical composition |
| 12/06/2001 | US20010049383 Gram-positive oxazolidinone agent; contact surface material is made of at least 50% polyolefin. |
| 12/06/2001 | US20010049382 Or nicotinic acid esters |
| 12/06/2001 | US20010049381 Non-immunosuppressive five-membered heterocyclic compound having a single nitrogen heteroatom, which has an N-linked ketone, diketo, thioketo, or 1-(2-(3-oxo) propene) substituent; additionally substituted with ester or amide |
| 12/06/2001 | US20010049380 Administering an insulin sensitiser and an insulin secretagogue |
| 12/06/2001 | US20010049378 Administering a gemifloxacin compound effective against penicillin-resistant and ciprofloxacin-resistant bacteria, especially resistant Streptococcus pneumontae. |
| 12/06/2001 | US20010049377 Glucocortiocoid-selective antiinflammatory agents |
| 12/06/2001 | US20010049376 Method of prevention of prostatic carcinoma with 17beta-N-monosubstituted-carbamoyl-4-aza-5alpha-androst-1-en-3-ones |
| 12/06/2001 | US20010049375 Neutral antagonists and use thereof in treating drug abuse |
| 12/06/2001 | US20010049373 Substituted 4-phenoxy-6-aminopyrimidines |
| 12/06/2001 | US20010049372 Antiviral nucleoside analogues |
| 12/06/2001 | US20010049371 Reducing levels of tumor necrosis factor alpha; inhibition of undesireable levels of matrix metalloproteinases |
| 12/06/2001 | US20010049369 Especially treating retinal detachment, age-related macular degeneration, retinitis pigmentosa; compound stimulates upregulation of glutamine synthetase in Muller cells. |
| 12/06/2001 | US20010049368 Administering the combination of: a PDE4 inhibitor; and a neurokinin-1 receptor antagonist or an alpha-2 adrenoreceptor agonist to minimize the side effect of nausea or emesis associated with the PDE4 inhibitor. |
| 12/06/2001 | US20010049366 Topical solution formulations containing an antibiotic and a corticosteroid |
| 12/06/2001 | US20010049365 Compositions and methods of treating abnormal cell proliferation |
| 12/06/2001 | US20010049364 Prevention of cancer |
| 12/06/2001 | US20010049363 At least one NSAID, thymol, methyl salicylate, menthol and eucalyptol; for treating and/or preventing gingivitis |
| 12/06/2001 | US20010049362 Phospholipid compositions as anti-inflammation agents |
| 12/06/2001 | US20010049359 Treatment of hiv infection |
| 12/06/2001 | US20010049352 Hydrolyzed whey protein; a carbohydrate source; and a lipid source including a mixture of medium and long chain triglycerides; caloric density of at least 1.4 kcal/mL; ratio of non-protein calories per gram nitrogen of at least 90:1. |
| 12/06/2001 | US20010049350 Adjusting the prolactin and melatonin profiles of the mammal by administering prolactin enhancers or reducers and melatonin so that the prolactin and melatonin profiles conform to or approach normal profiles |
| 12/06/2001 | US20010049349 Antioxidant enhancement of therapy for hyperproliferative conditions |
| 12/06/2001 | US20010049144 Genetically engineering a primate for expression of a desired gene, comprising introducing into the primate a transgene of a Rous Sarcoma Virus promoter (RSV) and a nucleic acid sequence heterologous to said RSV promoter; gene therapy |
| 12/06/2001 | US20010049137 DNA fragments derived from the genomic DNA of HPV-33, including recombinant vectors, which cells are replicated in host cells and expressed as immunogenic proteins; diagnosis of tumors; antibodies to detect viral infections |
| 12/06/2001 | US20010049113 Treating a vial infection which uses the host cell Ras pathway with agents that inhibit Ras pathway, agents that promote protein kinase (PKR) phosphorylation, or that promote translation initiation factor eIF-2 alpha phosphorylation |
| 12/06/2001 | US20010049106 ADAM (A Disintegrin And Metalloprotease) family of metalloproteases, and in addition contain thrombospondin domain (TS); treating diabetes, arthritis, cancer, solid tumors, autoimmune diseases |
| 12/06/2001 | US20010048952 Mixture of aloe vera, collagen, chromium compounds and linoleic acid |
| 12/06/2001 | US20010048951 Reduced concentration of carbon dioxide |
| 12/06/2001 | US20010048946 Drug in water soluble polymer matrix |
| 12/06/2001 | US20010048945 Sustained drug release |
| 12/06/2001 | US20010048944 Antibiotic product, use and formulation thereof |
| 12/06/2001 | US20010048943 Osmotic device containing venlafaxine and an anti-psychotic agent |
| 12/06/2001 | US20010048942 Hormone and enzyme inhibitor |
| 12/06/2001 | US20010048941 Method for treating amyloidosis |
| 12/06/2001 | US20010048938 TTS containing an antioxidant |
| 12/06/2001 | US20010048932 Inhibition of hair growth |
| 12/06/2001 | US20010048915 Decreased endogenous nitric oxide activation |
| 12/06/2001 | DE10050267A1 Dental and/or oral cleaning agent, such as toothpaste, tooth gel, tooth powder, medicinal chewing gum, mouthwash, mouth powder, mouth pill or toothpick, comprises psychopharmaceutical |
| 12/06/2001 | DE10027025A1 Clycinamide Clycinamide |
| 12/06/2001 | DE10027024A1 Carbaminsäureester Carbamic |
| 12/06/2001 | DE10026699A1 Formulierung auf Heparin-, Glycosaminoglycan- oder Heparinoidbasis und Verwendung der Formulierung sowie der Formulierungsgrundlage Formulation of heparin, glycosaminoglycan or Heparinoidbasis and use of the formulation and the formulation base |
| 12/06/2001 | DE10025464A1 Kombinierte Verwendung von Enzyminhibitoren zur Therapie von Autoimmunerkrankungen, bei Transplantationen und Tumorerkrankungen sowie Kombinationen von Enzyminhibitoren umfassende pharmazeutische Zubereitungen Combined use of enzyme inhibitors for the therapy of autoimmune diseases, transplantation and tumor diseases as well as combinations of enzyme inhibitors pharmaceutical preparations comprising |
| 12/06/2001 | DE10025328A1 Acetylsalicylsäure enthaltendes superfizielles therapeutisches System zur Behandlung von Hautschmerzen Superficial therapeutic system containing acetylsalicylic acid for treating skin pain |
| 12/06/2001 | DE10025152A1 Treatment of noise- or age-induced hearing deficiency, comprises using neurotrophin stimulating agents to counteract cochlear neurodegeneration |
| 12/06/2001 | CA2736344A1 Tnf-.alpha. production inhibitors |